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powerful target for therapeutic intervention (4), 
the mechanisms of perivascular microglia acti-
vation in infl ammatory demyelination as well as 
a strategy to limit their activation in MS have 
not been identifi ed.
In MS lesions, perivascular activation of 
microglia colocalizes with areas of blood-
brain barrier (BBB) disruption (5). Magnetic 
resonance imaging studies link BBB break-
down with clinical relapse (6). Moreover, in 
vivo live imaging showed that BBB disrup-
tion provokes the immediate and focal activa-
tion of microglia (7). However, the molecular 
mechanism that links BBB disruption with 
microglia activation and disease pathogenesis 
remains elusive. One of the earliest events 
coupled to BBB disruption in MS is leakage 
of the blood protein fi brinogen in the ner-
vous system that results in perivascular depo-
sition of fi brin (8-11). Although fi brinogen 
has been primarily studied for its functions 
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Perivascular microglia activation is a hallmark of infl ammatory demyelination in multiple 
sclerosis (MS), but the mechanisms underlying microglia activation and specifi c strategies 
to attenuate their activation remain elusive. Here, we identify fi brinogen as a novel 
 regulator of microglia activation and show that targeting of the interaction of fi brinogen 
with the microglia integrin receptor Mac-1 (𝛂M𝛃2, CD11b/CD18) is suffi cient to suppress 
 experimental autoimmune encephalomyelitis in mice that retain full coagulation function. 
We show that fi brinogen, which is deposited perivascularly in MS plaques, signals through 
Mac-1 and induces the differentiation of microglia to phagocytes via activation of Akt and 
Rho. Genetic disruption of fi brinogen–Mac-1 interaction in fi brinogen-𝛄390-396A knock-in 
mice or pharmacologically impeding fi brinogen–Mac-1 interaction through intranasal 
delivery of a fi brinogen-derived inhibitory peptide (𝛄377-395) attenuates microglia activation 
and suppresses relapsing paralysis. Because blocking fi brinogen–Mac-1 interactions affects 
the proinfl ammatory but not the procoagulant properties of fi brinogen, targeting the 
𝛄377-395 fi brinogen epitope could represent a potential therapeutic strategy for MS and 
other neuroinfl ammatory diseases associated with blood-brain barrier  disruption and 
 microglia activation.
Multiple sclerosis (MS) is a chronic infl amma-
tory demyelinating disease of the nervous system 
in which an infl ammatory process is associated 
with destruction of myelin sheaths and later 
with axonal damage leading to permanent 
functional defi cits, such as paralysis and loss of 
vision (1). Resident microglia are considered 
responsible for the eff ector mechanism leading 
to demyelination via their ability to phagocytose 
myelin and secrete proinfl ammatory cytokines 
(2). Microglia are necessary not only for the 
maintenance but also for the onset of infl am-
matory demyelination in central nervous sys-
tem (CNS) autoimmune disease (3), suggesting 
that attenuation of the microglia response could 
represent a promising therapeutic target for MS 
(2). Although microglia represent a potentially 
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in blood coagulation, there is  appreciable evidence that fi -
brinogen plays a pivotal role in the infl ammatory response 
(12, 13) and host defense (14, 15). Fibrinogen is a classic 
acute-phase reactant, characterized by a unique molecular 
structure with binding sites for  cellular receptors that regu-
late the infl ammatory process (16, 17). Research in MS ani-
mal models shows that prophylactic fi brin depletion either 
by genetic depletion of fi brinogen (18) or by prophylactic 
administration of anti- coagulants (18, 19) ameliorates dis-
ease pathogenesis. Although these studies show that pro-
phylactic depletion of fi brin could be benefi cial in MS, the 
use of anti-coagulants would potentially have limited thera-
peutic value due to the hemorrhagic side eff ects after pro-
longed use of fi brin-depleting agents.
We sought to design a therapeutic strategy that would 
block the damaging eff ects of fi brinogen in the nervous sys-
tem without aff ecting its benefi cial eff ects in blood coagula-
tion by identifying and targeting the fi brinogen receptor in 
the nervous system. Impeding the interaction of fi brinogen 
with selected integrin receptors has been previously used as 
a strategy for drug development. Disruption of fi brinogen 
interaction with the platelet integrin receptor αIIbβ3 using 
either small molecule inhibitors or antibodies (e.g., ReoPro, 
abciximab) is highly eff ective at limiting thrombotic events 
in patients with vessel wall disease (20). We hypothesized 
that if we identifi ed the specifi c cell type in the CNS respon-
sive to fi brinogen and established the specifi c fi brinogen 
 receptor used by these cells, we may be able to block the dele-
terious cellular responses associated with fi brin deposition 
in the nervous system without aff ecting its benefi cial coagu-
lant properties.
Recent evidence showed that paralysis of CD11b+ mi-
croglia ameliorates infl ammatory demyelination in the pres-
ence of peripheral T cells and macrophages (3). CD11b is 
the α chain of the integrin receptor Mac-1 (αMβ2, CD11b/
CD18) that in infl ammatory demyelination regulates phago-
cytosis of myelin (21, 22). Myelin phagocytosis is thought to 
be subjected to modulation between inactive and active states 
of Mac-1 (23). Immobilized fi brinogen and insoluble fi brin, 
but not soluble fi brinogen, have been identifi ed as physiolog-
ical, high-affi  nity ligands for Mac-1 (15, 24, 25). Interest-
ingly, in MS lesions fi brin deposition colocalizes with areas of 
activated microglia (11). Here, we show that fi brinogen con-
trols diff erentiation of microglia to phagocytes via the integ-
rin receptor Mac-1. Moreover, a fi brinogen-derived peptide 
known to inhibit Mac-1 (γ377-395 peptide) blocks microglia 
activation in vitro. Importantly, complementary in vivo studies 
using either the inhibitory γ377-395 peptide or mice express-
ing a mutant form of fi brinogen lacking the Mac-1 binding 
motif establish that targeting the fi brin–Mac-1 interaction is 
a novel and potentially eff ective therapeutic strategy for in-
fl ammatory demyelination. These studies show for the fi rst 
time that fi brin induces microglia activation and that target-
ing the infl ammatory but not the procoagulant properties of 
fi brinogen is suffi  cient to suppress microglia activation and 
infl ammatory demyelinating disease.
RESULTS
Fibrinogen directly activates microglia resulting 
in cytoskeletal rearrangements and increased phagocytosis
We fi rst tested the eff ects of fi brinogen on pure primary mi-
croglia cells. Immobilized fi brinogen had a dramatic eff ect on 
microglia activation characterized by an increase in cell size 
(Fig. 1 A, top right) when compared with untreated controls 
(Fig. 1 A, top left). Quantitation revealed 85.5 ± 1.4% of acti-
vated microglia after fi brinogen treatment versus 8.2 ± 3.4% 
in untreated cells (Fig. 1 B; P < 0.001). In contrast to immo-
bilized fi brinogen, soluble fi brinogen did not induce changes 
in microglia morphology (not depicted). LPS was used as 
a positive control (Fig. 1, A and B). Using an endotoxin de-
termination assay, we verifi ed that there was no LPS con-
tamination in the fi brinogen-treated cultures. To assess the 
functional eff ect of this morphologic activation, we performed 
phagocytosis assays. Fibrinogen stimulation resulted in a 65.3% 
Figure 1. Fibrinogen directly activates microglia resulting in cyto-
skeletal rearrangements and increased phagocytosis. (A) IsoB4/DAPI 
immunostained microglia cultured on immobilized fi brinogen have in-
creased cell body size adopting an amoeboid morphology (right). Untreated 
primary microglia show small cell bodies and thin, bipolar processes 
(left). LPS-treated cells show activated morphology characterized by cell 
body swelling (middle). Bar, 26 μm; inset, 21 μm. (B) Quantitation of 
 microglia activation reveals a dramatic increase upon fi brinogen stimulation. 
(C) Fibrinogen-stimulated microglia showed increased phagocytosis of 
 fl uorescent Escherichia coli as compared with untreated microglia. LPS 
served as a positive control. (D) Deconvolution microscopy of primary 
microglia revealed signifi cant rearrangements of the cytoskeleton upon treat-
ment with fi brinogen. Microglia were stained with antibodies to actin and 
β-tubulin in red, and the nucleus was stained blue with DAPI. Bar, 4.4 μm.
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increase in phagocytosis as compared with untreated controls 
(P < 0.05), whereas LPS incubation, by comparison, increased 
phagocytosis by 39.1% (Fig. 1 C; P < 0.05). Previous studies 
have demonstrated that dynamic rearrangements of both 
the actin (26) and microtubule (27) networks are critical for 
phagocytosis. Deconvolution microscopy showed that fi brin-
ogen stimulation resulted in dramatic rearrangement of the 
 microglial cytoskeleton as determined by immunostaining of 
actin and β-tubulin (Fig. 1 D). Collectively, these results 
suggest that fi brinogen induces microglia diff erentiation 
into a phagocytic state.
Fibrinogen activates microglia via the Mac-1 
integrin receptor
Mac-1 orchestrates the innate immune response by regu-
lating phagocyte adhesion, migration, and engulfment of 
complement-opsonized particles (28). M1/70, an antibody 
that blocks binding of fi brinogen to CD11b (24, 29), inhib-
ited fi brinogen-mediated microglia activation (Fig. 2 A). 
 Quantitation showed 71 ± 4.9% of activated microglia in 
fi brinogen-treated cells versus 18 ± 0.7% in cells treated with 
fi brinogen in the presence of M1/70 (Fig. 2 B; P < 0.01). The 
inhibitory eff ect of M1/70 was specifi c for fi brinogen and 
did not aff ect LPS-mediated activation of microglia (Fig. 2 B). 
Moreover, blocking CD11b reduced phagocytosis of fi brino-
gen-treated cells by 40% (Fig. 2 C; P < 0.05). Previous studies 
have established that the Toll-like receptor (TLR)4 LPS re-
ceptor mediates LPS-induced microglia activation (30, 31). In 
contrast, blocking TLR-4 did not aff ect fi brinogen-mediated 
phagocytosis, suggesting that Mac-1 was the major receptor 
to induce fi brinogen-mediated phagocytosis (Fig. 2 C).
RhoA and phosphoinositide 3-kinase (PI3K) are the two 
major signaling pathways downstream of Mac-1 that mediate 
the cytoskeletal rearrangements for the induction of phago-
cytosis (28, 32, 33). Fibrinogen induced a 1.9-fold increase of 
active RhoA and a 24-fold increase in Akt phosphorylation 
in microglia (Fig. 2 D). Furthermore, blocking the PI3K sig-
naling pathway using LY294002 inhibited the fi brinogen-
 induced increase of phagocytosis in microglia (Fig. 2 C; P < 
0.01), suggesting that PI3K is downstream of fi brinogen–
Mac-1 signaling in microglia cells. This is the fi rst evidence sug-
gesting that fi brinogen can induce Mac-1–dependent signaling 
in microglia.
Analysis of demyelinated spinal cords after the induction 
of proteolipid protein (PLP)139-151 experimental autoimmune 
encephalomyelitis (EAE) in mice showed that CD11b+ mi-
croglia (Fig. 2 E, green) were surrounded by fi brin (Fig. 2 E, 
red). Similarly, analysis of acute demyelinating lesions of 
 human MS showed that fi brin (Fig. 2 F, green) surrounded 
activated microglia cells (Fig. 2 F, red). Collectively, these results 
show that fi brinogen/CD11b signaling induces  phagocytosis 
in microglia and demonstrate both in EAE and in human MS 
Figure 2. Fibrinogen directly activates microglia via the Mac-1 
integrin receptor. (A) Fibrinogen-induced morphologic activation of 
microglia is blocked by the addition of a rat anti-CD11b neutralizing anti-
body (M1/70). Rat IgG (control) did not change the effects of fi brinogen 
in microglia activation. Bar, 39 μm; inset, 17 μm. (B) Quantitation of 
microglia activation reveals that the Mac-1 neutralizing antibody blocks 
fibrinogen-induced activation but not LPS activation of microglia. 
(C) Increased microglia phagocytosis upon fi brinogen stimulation is blocked 
by the addition of a PI3K inhibitor (LY294002) and diminished in the presence 
of a CD11b neutralizing antibody. A control anti-TLR4 or IgG showed no 
reduction in fi brinogen-stimulated phagocytosis. (D) Western blots show 
increased active RhoA and Akt activation upon fi brinogen stimulation of 
microglia. In both assays, LPS served as a positive control. (E) Confocal 
microscopy demonstrates the spatial interaction between CD11b+ cells 
(green) and fi brin (red) in spinal cords from PLP139-151– immunized mice. 
(F) Confocal double immunofl uorescence shows fi brin (green) surrounding 
an activated microglia (red) in a human early demyelinating plaque of 
acute MS. Bars: E, 6.7 μm; F, 15 μm.
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the presence of this ligand–receptor system on active microglia 
within infl ammatory demyelinating lesions.
Fibrin depletion inhibits microglia activation in vivo 
and attenuates infl ammatory demyelination
We further examined whether fi brin is required for the 
 activation of Mac-1+ cells in vivo. We administered the anti-
coagulant ancrod (34) in an established remitting-relapsing 
model of PLP139-151 EAE (35) after the development of the 
fi rst paralytic incidence. At the time of the fi rst relapse, un-
treated mice show dramatic activation of CD11b+ cells char-
acterized by thick processes (Fig. 3 A, left, green). In contrast, 
in ancrod-treated mice, CD11b+ cells appear with ramifi ed 
morphology (Fig. 3 A, right, green) resembling CD11b+ cells 
in the normal spinal cord (Fig. S1, available at http://www
.jem.org/cgi/content/full/jem.20061931/DC1). Single chan-
nel images are shown in Fig. S1. Untreated mice showed ex-
tensive infl ammatory demyelinating lesions in the cerebellum 
(Fig. S2, asterisk) and spinal cord (Fig. S2, arrows). In  contrast, 
in ancrod-treated mice, infl ammatory demyelination was dra-
matically decreased (Fig. S2). Ancrod treatment  resulted in 
decreased demyelination by sevenfold in the cerebellum and 
by twofold in the spinal cord. Splenocytes isolated from 
untreated and ancrod-treated mice showed no diff erence in 
proliferation upon stimulation with PLP139-151 (Fig. S3), fur-
ther suggesting that CD11b+ cells are the major cell target of 
fi brin in the nervous system. Fibrin-depleted mice recovered 
faster from the fi rst paralytic incidence and in contrast to con-
trol mice never relapsed (Fig. 3 B). In a rotarod behavioral 
test performed before the fi rst relapse of the  untreated group, 
fi brin-depleted mice showed a threefold  increase of motor 
strength and coordination when compared with the untreated 
group (Fig. 3 C). Control nonimmunized mice show values 
of 500 s on this assay. Collectively, these results suggest that 
fi brin is a major contributor to the local activation of CD11b+ 
cells in vivo. In addition, this is the fi rst demonstration that an 
anti-coagulant may improve clinical symptoms and reduce in-
fl ammatory demyelination when  administered after the onset 
of paralytic symptoms.
Fib𝛄390-396A mice have reduced clinical scores 
and CNS infl ammatory lesions
To examine the contribution of fi brinogen–Mac-1 signaling 
in vivo, we used mice with a knock-in mutation of seven 
amino acids at residues (N390RLSIGE396) to alanine residues 
(A390AAAAAA396) that abolishes fi brinogen binding to the 
Mac-1 receptor (15). These mice, termed Fib𝛄390-396A, show 
decreased Mac-1–mediated neutrophil adhesion resulting 
in decreased bacterial clearance (15). Fib𝛄390-396A and their 
age- and sex-matched littermate controls (Fib𝛄WT) were 
backcrossed six generations to C57BL/6 background (15) 
and immunized with myelin oligodendrocyte glycoprotein 
(MOG)35-55 peptide (Fig. 4 A). Fib𝛄390-396A mice (n = 29) 
showed an average clinical score of 2.1 ± 0.32 (ataxia) at day 
20 after immunization, whereas the Fib𝛄WT mice (n = 28) 
developed clinical symptoms of paralysis, showing an average 
score of 3.3 ± 0.22 (hind limb paralysis; P < 0.01). On day 
20, in the Fib𝛄WT mouse group, 74% of Fib𝛄WT mice (14/19) 
were paralyzed, in contrast to 35% of Fib𝛄390-396A mice (7/20; 
clinical score > 3; Fig. 4 B), further demonstrating decreased 
severity of EAE. Fib𝛄390-396A mice showed a 1.5-fold increase 
in motor skills when compared with Fib𝛄WT mice (Fib𝛄390-396A, 
269 ± 9 s vs. Fib𝛄WT, 169 ± 23 s; P < 0.05; Fig. 4 E). Infl am-
matory lesions were decreased threefold in Fib𝛄390-396A mice 
when compared with Fib𝛄WT (Fig. 4 C; P < 0.05). Demye-
lination was reduced in Fib𝛄390-396A mice (1.57 ± 0.89%) 
when compared with Fib𝛄WT (4.17 ± 0.83%; P < 0.04). In 
accordance, spinal cord sections showed a decrease of IsoB4+ 
cells in Fib𝛄390-396A mice when compared with Fib𝛄WT con-
trols (Fig. 4 F). Decrease in clinical severity was also observed 
at later time points after the immunization (Fig. 4, A and B). 
In addition, 25% of Fib𝛄WT mice (7/28) died compared with 
only 3% of the Fib𝛄390-396A mice (1/29; Fig. 4 D; P < 0.03). 
Collectively, these results suggest that the γ390-396 binding site 
of fi brinogen to Mac-1 regulates the severity of EAE.
The fi brin 𝛄377-395 peptide blocks microglia activation in vitro
Both the in vitro (Fig. 2) and in vivo experiments (Fig. 4) 
show that fi brinogen signaling through the Mac-1 receptor 
contributes to microglia activation and regulates the severity 
of EAE. Biochemical studies identifi ed that the γ377Y S M K K-
T T M K I I P F N R L T I G 395 peptide blocks fi brin binding to 
Mac-1 (29). The γ377-395 is a cryptic epitope in the fi brinogen 
Figure 3. Fibrin depletion using ancrod reverses relapsing paralysis 
and reduces microglia activation in EAE. (A) Immunofl uorescence 
of control (left) and fi brin-depleted (right) spinal cord with antibodies 
against fi brinogen (red) and CD11b (green). Activated CD11b+ cells 
 colocalize with fi brin deposition in the control spinal cord (yellow). Bar, 
8.4 μm. (B) Clinical scores of PLP139-151–immunized mice. Fibrin depletion 
begins after the fi rst paralytic episode. Fibrin-depleted mice (red circles; 
n = 8) did not develop fi rst or second relapses as compared with control 
mice (black circles; n = 10). (C) Rotarod motor strength and coordination 
test. Fibrin-depleted mice outperformed immunized control untreated 
mice on day 25 after immunization. Data are represented as the mean 
clinical score and are mean ± SEM.
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molecule and is exposed only when fi brinogen is immobilized 
or converted to fi brin (25, 36). We used 200 μM of pep-
tide, a concentration shown to inhibit adhesion of Mac-1–
 overexpressing cells to immobilized fi brinogen (37), to examine 
whether the γ377-395 peptide could inhibit microglia activa-
tion. Fibrinogen treatment resulted in 71 ± 4.9% of activated 
microglia when compared with 38.3 ± 9.8% after the 
 addition of the γ377-395 peptide (Fig. 5, A and B; P < 0.05), 
suggesting that the γ377-395 peptide reduced fi brin-mediated 
microglia activation. The γ377-395 peptide did not aff ect the 
activation state of untreated microglia and did not inhibit 
LPS-mediated microglia activation (Fig. 5 B), further sug-
gesting the specifi city of γ377-395 to block the activation of 
Mac-1 by fi brin. In accordance, examination of Akt phos-
phorylation showed that the γ377-395 peptide could specifi cally 
inhibit fi brin-mediated and not LPS-mediated phosphoryla-
tion of Akt (Fig. 5 C). Overall, these results suggest that in-
hibition of fi brin–Mac-1 interactions by the γ377-395 peptide 
inhibits both the morphological activation and the signaling 
cascade induced by fi brin-mediated activation of the Mac-1 
microglia receptor.
Prophylactic or therapeutic administration of the fi brin 
𝛄377-395 peptide suppresses EAE and inhibits microglia 
activation in vivo
Because genetic studies showed that the γ377-395 binding 
 epitope of fi brinogen to Mac-1 is not involved in coagulation 
(15) but is suffi  cient to inhibit fi brin-mediated microglia acti-
vation (Figs. 4 and 5), we examined whether blocking ex-
clusively the infl ammatory properties of fi brinogen in vivo 
using the γ377-395 would be suffi  cient to ameliorate EAE. We 
therefore examined the eff ects of in vivo administration of 
the γ377-395 fi brin peptide on microglia activation and clinical 
progression in an animal model for MS. We fi rst assessed the 
eff ects of vaccination against γ377-395 peptide. Vaccination 
with γ377-395 peptide before the induction of EAE resulted in 
a signifi cant reduction in disease penetrance and clinical 
symptoms. All control mice (15/15) developed clinical symp-
toms of EAE. In contrast, only 53% of the vaccinated mice 
(8/15) developed EAE. Moreover, mice vaccinated with the 
γ377-395 peptide showed an average clinical score of 1.1, 
whereas the control group showed a score of 2.5 (Fig. 6 A; 
P < 0.01). In a rotarod test, vaccinated mice showed a 76% 
increase in motor strength and coordination when compared 
with the control mice. Quantitative histopathological analysis 
showed reduced infl ammatory lesions in the cerebellum 
(index of 6.5 ± 5.9 vs. 12 ± 5.2; P < 0.05) and spinal cord 
(index of 1.5 ± 2 vs. 2.3 ± 1; P < 0.01) from γ377-395 peptide–
vaccinated mice as compared with control mice.
Because vaccination is a preventive treatment, we further 
assessed whether γ377-395 peptide would be benefi cial if ad-
ministered after the onset of disease. We administered in-
tranasally 30 μg γ377-395 peptide daily after the fi rst paralytic 
episode in remitting relapsing EAE (35). Intranasal delivery 
Figure 4. Fib𝛄390-396A mice have reduced clinical scores and 
microglia activation in EAE. (A) Clinical scores of MOG35-55–immunized 
mice. Fib𝛄390-396A mice (blue triangles; n = 29) show statistically signifi -
cant lower clinical scores (*, P < 0.01) than Fib𝛄WT control mice (black 
squares; n = 28). (B) Individual clinical scores from Fib𝛄390-396A and Fib𝛄WT 
mice on days 20 (average clinical score, 3.3 ± 0.22 for Fib𝛄WT [n = 19] vs. 
2.1 ± 0.32 for Fib𝛄390-396A [n = 20]; P < 0.01) and 31 after immunization 
(average clinical score, 2.8 ± 0.25 for Fib𝛄WT [n = 15] vs. 1.5 ± 0.23 for 
Fib𝛄390-396A [n = 20]; P < 0.001). (C) Histological analysis of spinal cord 
sections stained with hematoxylin/eosin revealed increased infl ammation in 
the Fib𝛄WT mice versus the Fib𝛄390-396A mice. (D) Survival curve of Fib𝛄390-396A 
and Fib𝛄WT mice after MOG35-55 immunization. Fib𝛄390-396A had a greater 
survival rate than the Fib𝛄WT mice. (E) Rotarod analysis of Fib𝛄390-396A and 
Fib𝛄WT mice on day 13. Fib𝛄390-396A signifi cantly outperformed their wild-type 
counterparts in a behavioral test designed to assess motor skill function. 
n = 7 mice per group. **, P < 0.05. (F) Increased activation of IsoB4+ cells 
in Fib𝛄WT mice as compared with Fib𝛄390-396A mice. Bar, 58 μm. Data are 
represented as the mean clinical score and are mean ± SEM.
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is a noninvasive delivery method that results in a higher 
degree of drug delivery to the nervous system and a lower 
degree of systemic drug delivery to tissues such as liver and 
lymph nodes when compared with intravenous delivery (38). 
Intranasal delivery has been previously shown to be eff ec-
tive as a method of drug delivery in EAE (39-41). γ377-395 
peptide–treated mice (n = 14) compared with control mice 
(n = 13) did not relapse (Fig. 6 B). Peptide-treated mice 
showed a 1.4-fold increase of motor functions when com-
pared with the control mice after the fi rst relapse on day 29. 
 Administration of scramble peptide had no eff ect on the 
progression of EAE (Fig. S5, available at http://www.jem
.org/cgi/content/full/jem.20061931/DC1).
Immunohistochemical analysis using Mac-3, a microglia/
macrophage marker, revealed reduction of activated cells 
in the peptide-treated (Fig. 6 D) as compared with control 
animals (Fig. 6 C). High magnifi cation images of Mac-3 im-
muno staining are shown in Fig. S6, which is available at 
http://www.jem.org/cgi/content/full/jem.20061931/DC1. 
In addition, inducible nitric oxide synthase (iNOS), a major 
pro duct of activated CD11b+ microglia in EAE (42), was 
reduced in the γ377-395 peptide–treated animals (Fig. 6 D,  inset). 
Quantitation of the histopathological analysis shows reduction 
in both Mac-3 (P < 0.05) and iNOS (P < 0.01), whereas 
there are no major diff erences in T cell infi ltrates (Fig. 6 E; 
P = 0.48). We further examined whether the γ377-395 peptide 
aff ected the peripheral immune response. FACS analysis on 
the splenocytes of mice immunized with PLP139-151 using six 
markers for peripheral immune cells, namely CD4 and CD8 
T cells, CD11b macrophages, CD11c dendritic cells, and 
CD19 and B220 B cells, did not reveal any diff erences be-
tween untreated and γ377-395 peptide–treated animals (Fig. S4), 
suggesting that similar to systemic fi brin depletion (Fig. S3), 
the γ377-395 peptide does not aff ect the peripheral immune 
response. These results are in accordance with prior studies in 
which depletion of macrophages (43) or microglia (3) resulted 
in dramatic reduction of clinical symptoms in EAE even in 
the presence of functional T cells.
The fi brin 𝛄377-395 peptide does not affect the coagulation 
properties of fi brinogen
Several studies have demonstrated both in vivo and in vitro 
that fi brinogen interacts with diff erent cellular receptors 
via non overlapping epitopes (for review see reference 16). 
Fibrinogen regulates blood coagulation by engaging the 
platelet αIIbβ3 integrin receptor via its γ408-411 epitope, whereas 
it mediates infl ammatory processes by engaging the Mac-1 
receptor via its γ377-395 epitope. As a result, fi brinogen knock-
in mice, where the γ390-396 Mac-1 binding site has been mu-
tated, show normal coagulation properties, such as platelet 
aggregation, thrombus formation, and clotting time (15). To 
determine whether the γ377-395 peptide interfered with blood 
coagulation, we examined its eff ects on the procoagulant 
properties of fi brinogen both in vivo and in vitro. As ex-
pected, the γ377-395 peptide does not aff ect coagulation in 
mice (Fig. 7 A) or prothrombin time (Fig. 7 B). Moreover, in 
an in vitro fi brin polymerization assay, the γ377-395 peptide did 
not alter the polymerization time of fi brin (Fig. 7 C). In con-
trast, the GPRP peptide, an established inhibitor of clot 
formation (44), inhibits fi brin polymerization (Fig. 7 C). 
Collectively, these results show that in vivo delivery of the 
γ377-395 peptide reduces the progression and severity of EAE 
by specifi cally targeting microglia/macrophage activation in 
the CNS parenchyma without adverse hemorrhagic eff ects.
DISCUSSION
In this study, we show for the fi rst time that inhibition of 
the infl ammatory but not the procoagulant properties of fi -
brinogen is suffi  cient to suppress clinical symptoms and dis-
ease pathogenesis in an animal model of MS. We show that 
fi brinogen–Mac-1 interaction induces signal transduction 
pathways that support the activation of microglia and have 
identifi ed the fi brinogen γ377-395 polypeptide that contains 
the Mac-1 binding motif as a therapeutic target for MS. Our 
study identifi es fi brinogen as a microglial activation signal 
and suggests the following model for the role of fi brin in in-
fl ammatory demyelination (also see Fig. 8): (a) Fibrinogen is 
not present within the extracellular matrix in any normal/ 
unchallenged tissue, including healthy CNS; (b) BBB 
Figure 5. The fi brin-derived 𝛄377-395 peptide inhibits microglia 
activation. (A) Microglia activation upon fibrinogen stimulation 
is attenuated in the presence of γ377-395. Bar, 33 μm; inset, 29 μm. 
(B) Quantitation of microglia activation reveals that γ377-395 diminishes 
fibrinogen-stimulated microglia activation but has no effect on 
LPS activation. (C) Treatment of microglia with γ377-395 blocks fi brinogen-
induced Akt activation in vitro. LPS activation of Akt is unaffected by 
γ377-395 treatment.
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 disruption, which precedes lesion development and clinical 
symptoms in MS (6, 45), permits the leakage of fi brinogen 
perivascularly in the brain; (c) Fibrinogen is converted to 
 fi brin either by cell-associated procoagulant factors (e.g., tissue 
factor) expressed within the nervous system or by blood-
borne procoagulants (46); (d) Fibrinogen conversion to fi brin 
allows the exposure of the cryptic Mac-1 binding motif 
in  fi brinogen associated with γ377-395 sequence (25, 36); 
(e) Fibrin–Mac-1 interactions induce local activation of mi-
croglia, including a fi brin-dependent activation of Akt and 
Rho signaling, resulting in cytoskeletal rearrangements and 
increased phagocytic capacity; (f) Fibrin-mediated microglia 
activation events lead to local degenerative and phagocytic 
alterations that determine the extent of tissue damage in MS. 
Therefore, because fi brinogen within the CNS becomes ap-
preciable only after injury or BBB disruption, it could serve 
as a matrix-associated “danger” signal and support infl amma-
tory processes. Given the colocalization of infl ammatory de-
myelinating lesions in MS with fi brin deposition, our data 
suggest that fi brinogen–Mac-1 interaction in the CNS pa-
renchyma is central to microglia activation and determines 
the area of  demyelination in MS.
Our study identifi es fi brinogen as a ligand for Mac-1 on 
microglia cells. Complement and in particular iC3b is well 
established as a ligand for Mac-1 (28). The presence of im-
munoglobulins and activated complement is restricted to the 
pattern II MS lesions (1). Because microglia activation and 
phagocytosis are common features for all subtypes of MS, 
other factors in the demyelinating lesion could potentially 
mediate microglia activation. Because BBB disruption is a 
common feature for diff erent types of MS lesions, our study 
suggests that fi brin could serve as a broad activation signal for 
microglia in the CNS. Determination of the temporal and 
spatial distribution of the diff erent Mac-1 ligands in MS 
plaques would provide crucial information for the activation 
of these cells in diff erent disease stages. Activation of microg-
lia contributes to both neuronal (47) and oligodendrocyte 
death (31) via release of cytokines and nitric oxide. The γ377-395 
peptide induced a reduction of iNOS+ microglia, suggesting 
that inhibition of fi brin–Mac-1 interaction reduces microglia 
activation that in MS could mediate secondary damaging 
eff ects on other cell types of the nervous system.
Prior studies have shown that genetic ablation of CD11b+ 
microglia (3) or antibodies against CD11b, such as M1/70 
(48), reduce symptoms in EAE. The present studies further 
underscore the importance of Mac-1 in microglial activa-
tion in EAE, but establish that the interaction of Mac-1 with 
one specifi c ligand, the provisional matrix protein fi brinogen, 
is central to the clinical progression of disease and CNS 
pathologies. A genetic alteration in the endogenous fi brin-
ogen γ chain gene that selectively eliminates the Mac-1 binding 
 motif is suffi  cient to ameliorate disease pathogenesis in EAE. 
Interestingly, mutating the Mac-1 binding motif on the 
 fi brinogen γ chain does not aff ect either the clotting function 
of fi brinogen or the engagement of Mac-1 with other ligands 
(15). Consistent with these fi ndings, pharmacologic disruption 
Figure 6. The fi brin-derived 𝛄377-395 peptide suppresses EAE. 
(A) Clinical scores from γ377-395 peptide–vaccinated mice. Mice were immu-
nized with γ377-395 peptide before EAE induction with PLP139-151 peptide. 
Vaccinated mice (blue triangles; n = 15) had signifi cantly reduced clinical 
scores as compared with control mice (black squares; n = 15). (B) Clinical 
scores from PLP139-151–immunized mice where the γ377-395 peptide was 
administered every day intranasally after the peak of the initial paralytic 
episode. γ377-395–treated mice (blue triangles; n = 14) did not show a 
relapse at approximately day 30 as compared with the controls (black 
squares; n = 13). *, P < 0.05; **, P < 0.01. Data are represented as the 
mean clinical score and are mean ± SEM. Immunostaining for Mac-3 and 
iNOS (inset) on day 30 after immunization shows dramatic reduction of 
microglia activation in the γ377-395 peptide–treated mice after EAE induc-
tion (D) when compared with control (C). Bar, 20 μm; inset, 10 μm. (E) Quan-
titation shows a twofold reduction in Mac-3 (P < 0.05) and a 4.2-fold 
reduction in iNOS (P < 0.01) after γ377-395 peptide treatment, whereas 
there are no major differences in T cell infi ltration.
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of fi brinogen–Mac-1 interaction with the fi brinogen- derived 
blocking γ377-395 peptide (37) also strongly alleviated CNS 
disease and did not aff ect coagulation. For peptide- recognizing 
integrin receptors, such as the RGD-recognizing αvβ3 and 
α5β1 integrins, both the peptide itself and antibodies against 
the peptide may inhibit integrin-mediated  biological eff ects 
(49-52). Similarly, the γ377-395 peptide was found not only to 
directly block fi brinogen–Mac-1–dependent microglial activa-
tion events both in vitro (Fig. 5) and in vivo (Fig. 6, B–E), but 
in addition, vaccination with the γ377-395 peptide protects 
from EAE (Fig. 6 A). One inference of this fi nding is that the 
generation of monoclonal antibodies against the γ377-395 epi-
tope could prove valuable therapeutic tools for MS.
Two previous studies have determined that pharmacologi-
cally depleting fi brinogen with snake venom–derived protease 
(ancrod) can prophylactically ameliorate symptoms of EAE (19, 
53). In this study, we further demonstrated that administra-
tion of ancrod can be benefi cial in limiting the clinical mani-
festations of EAE even after the onset of paralysis (Fig. 3 and 
Figs. S1 and S2). Although genetic or pharmacological deple-
tion of fi brinogen illustrates the contribution of fi brinogen to 
infl ammatory demyelinating disease, the clinical value of sup-
pression of coagulation with ancrod in the context of a chronic 
disease such as MS would depend upon the potential adverse 
hemorrhagic eff ects. The eff ective suppression of EAE observed 
in mice that either express a form of fully clottable fi brinogen 
that lacks the Mac-1 binding motif or were treated with the 
γ377-395 peptide that has no anticoagulatant eff ects indicates that 
functional properties of fi brinogen can be therapeutically tar-
geted without necessarily compromising hemostasis. More de-
tailed dose and pharmacological studies focusing on the γ377-395 
peptide or small molecule  mimetics will be necessary to reveal 
the potential eff ectiveness of this class of inhibitor in the treat-
ment of infl ammatory demyelinating disease.
An interesting unresolved question is the importance of 
the fi brinogen platelet integrin receptor αIIbβ3 in the progres-
sion of MS. Notably, αIIbβ3 transcripts are present in chronic 
MS lesions (54), supporting prior evidence for the presence 
of platelets in infl ammatory demyelinating lesions  (55). The 
clinical benefi ts associated with the mutant form of fi brino-
gen expressed by Fibγ390-396A mice are not likely to be due to 
any platelet-related process because these mice have been 
shown to support normal platelet aggregation in vitro and 
normal platelet thrombus formation in vivo (15). However, 
the potential contribution of fi brin–αIIbβ3 interactions in dis-
ease pathogenesis in MS could be readily defi ned in available 
mice either lacking αIIb or expressing a mutant form of fi -
brinogen lacking the αIIbβ3 binding motif.
Fibrin–Mac-1–mediated activation of monocyte cells is 
well established (17). Therefore, in addition to microglia 
act ivation, the γ377-395 fi brin peptide could inhibit the local 
Figure 7. The fi brin-derived 𝛄377-395 peptide does not affect 
in vivo coagulation or fi brin polymerization. In vivo clotting time (A) and 
prothrombin times (B) were assayed in the presence of 30 μg γ377-395 
peptide, the dose administered in vivo daily, and 90 μg γ377-395 peptide. 
Neither dose affected blood clotting times. (C) In vitro fi brin polymeriza-
tion was examined in the presence of the γ377-395 peptide. GPRP, a known 
inhibitor of fi brin formation, signifi cantly attenuated fi brin formation, 
whereas the γ377-395 peptide had no effect on fi brin polymerization.
Figure 8. Proposed model for the role of fi brin-induced activation 
of microglia in infl ammatory demyelination. BBB disruption permits 
the leakage of fi brinogen, the high affi nity ligand for Mac-1, in the CNS 
parenchyma. Fibrinogen is converted to fi brin and functions as the spatial 
signal to induce local activation of microglia via activation of the Mac-1 
integrin receptor and induction of signaling pathways downstream of 
Mac-1, such as Akt and Rho, resulting in phagocytosis that could deter-
mine the extent of tissue damage in infl ammatory demyelination.
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act ivation and possibly migration of peripheral macrophages 
in infl ammatory demyelination. Our study shows that fi brin-
ogen depletion or treatment with the γ377-395 peptide attenu-
ates the clinical symptoms in EAE by primarily ameliorating 
the microglia/macrophage response without interfering with 
T cell activation. These results are in accordance with previ-
ous studies that have established that not only depletion of 
macrophages (43) or microglia (3) in EAE results in ameliora-
tion of clinical symptoms in the presence of functional T cell 
activation, but also that induction of monocyte and dendritic 
cell activation can lead to infl ammatory demyelination even 
in the absence of T cells (56). In addition to CD11b, fi brino-
gen binds to the CD11c chain of the CD11c/CD18 integrin 
(57). The γ377-395 fi brin  peptide blocks the binding of fi brino-
gen to both CD11b and CD11c integrins (36). The CD11c+ 
perivascular dendritic cells are responsible for the presenta-
tion of myelin antigens (58, 59). Whether fi brinogen as a 
ligand for CD11c/CD18 could regulate the cross talk of den-
dritic cells with T cells in the perivascular space in infl amma-
tory demyelination remains to be resolved. This is of particular 
interest because recent studies demonstrated that microglia 
activation regulates leukocyte recruitment (60). Because the 
γ377-395 fi brin peptide blocks the binding of fi brin to both 
CD11b and CD11c integrins, it is possible that targeting the 
γ377-395 epitope could diminish the activation of both paren-
chymal (CD11b+) and dendritic (CD11c+) microglia. More 
detailed studies will be required to establish whether fi brin 
aff ects the cross talk of microglia with cells that are damaged 
during infl ammatory demyelination (61), such as oligoden-
drocytes and neurons.
Our study has identifi ed the inhibition of fi brin–Mac-1 
interactions as a novel strategy for the attenuation of the 
 microglia/macrophage activation in the CNS. Histopatho-
logical studies in acute MS have identifi ed perivenous lesions 
that appear to be driven by activated microglia/macrophages 
sometimes in the absence of lymphocytes (62, 63). Although 
the activation of microglia and macrophages plays a central 
role in the pathogenesis of MS (3, 4, 43, 63), agents that in-
hibit the microglia/macrophage response have not been de-
veloped (64). Although MS is a disease with profound lesion 
heterogeneity, BBB disruption and microglia activation are 
common features for the four diff erent subtypes of MS lesions 
(1). Therefore, targeting fi brin– Mac-1 interactions could be 
benefi cial in diff erent MS subtypes as a microglia-suppressive 
therapy and could be used in combinational therapies target-
ing other aspects of MS pathogenesis. In addition to MS, 
 microglia activation is observed in a variety of neurodegen-
erative diseases characterized by BBB disruption, such as 
spinal cord injury, stroke, and Alzheimer’s disease (16). It is 
therefore possible that targeting fi brin–Mac-1 interactions 
could represent a strategy for inhibiting microglia activation 
in neurodegenerative diseases. Because blocking fi brin–Mac-1 
interactions does not interfere with the physiological prop-
erties of fi brin in blood coagulation, this strategy could be 
applied in chronic diseases such as MS without hemorrhagic 
side eff ects.
MATERIALS AND METHODS
Animals. 6-wk-old female SJL/J and C57BL/6 mice were purchased 
from The Jackson Laboratory or Harlan Sprague Dawley. 6-wk-old female 
Fib𝛄390-396A mice were generated from double heterozygous matings to 
produce homozygous Fib𝛄390-396A mice (15) and Fib𝛄WT littermate mice as 
controls. Fib𝛄390-396A mice were backcrossed six generations to C57BL/6 
mice (15). All experiments were approved by the University of California, 
San Diego, Institutional Animal Care and Use Committee.
Induction of EAE. EAE was induced in 6-wk-old female SJL/J or 
C57BL/6 mice by subcutaneous immunization with 150 μg PLP139-151 
(H S L G K W L G H P D K F ; American Peptide Company and Azco Pharmchem) 
or 50 μg MOG35-55 (M E V G W Y R S P F S R V V H L Y R D G K ; Sigma-Aldrich) 
in complete Freund’s adjuvant (Sigma-Aldrich) supplemented with 200 ng 
of heat-inactivated mycobacterium tuberculosis H37Ra (Difco Labora-
tories). Mice were injected intravenously with 200 ng pertussis toxin (Sigma-
Aldrich) on days 0 and 2 of the immunization. Mice were scored daily as 
follows: 0, no symptoms; 1, loss of tail tone; 2, ataxia; 3, hindlimb paralysis; 
4, hindlimb and forelimb paralysis; 5, moribund. Data are represented as the 
mean clinical score and are mean ± SEM, and the Mann-Whitney test was 
used for statistical analysis. For the survival curve, statistical analysis was per-
formed with the log-rank test using PRISM software.
Systemic defi brinogenation. Mice were depleted of fi brinogen as de-
scribed previously (65). The pumps deliver 0.5 μl/hour; thus, the mice 
 received 2.4 U ancrod/day. In control animals, buff er-fi lled mini-pumps 
were implanted.
Fibrinogen 𝛄377-395 peptide vaccination. Vaccination was performed as 
described previously (66) with the following modifi cations. 5-wk-old female 
SJL/J mice were immunized with 200 μg fi brinogen γ377-395 peptide (Y S M-
K E T T M K I I P F N R L S I G ; Azco Pharmchem) emulsifi ed with an equal volume 
of incomplete Freund’s adjuvant (Sigma-Aldrich). Mice were immunized 
four times in alternating rear fl anks over the course of 2 wk. Control animals 
were immunized with incomplete Freund’s adjuvant.
Intranasal 𝛄377-395 peptide administration. Fibrinogen γ377-395 peptide 
(Y S M K E T T M K I I P F N R L S I G ; Azco Pharmchem) or scramble peptide 
(K M M I S Y T F P I E R T G L I S N K ; Azco Pharmchem) was resuspended in 0.9% 
NaCl at a concentration of 3 mg/ml. Peptides were aliquoted as single doses 
and stored at −20°C. Mice were administered 5 μl peptide or 0.9% NaCl as 
a control in each nare daily using a P10 micropipettor (Gilson) beginning 
 after the peak of the fi rst paralytic episode.
Histopathology. Histopathologic analysis and quantitation of infl ammation 
and demyelination in mouse tissue were performed on cryostat or paraffi  n 
sections as described previously (67). Sections were stained with hematoxylin/
eosin and luxol fast blue/nuclear red. Spinal cord sections were fi xed with 
2% paraformaldehyde for 10 min at 4°C and immunostained with a sheep 
anti-fi brinogen antibody (1:200; US Biological), rat anti-CD11b (1:5; 
Chemicon), von Willebrand Factor (1:1,000; DakoCytomation), iNOS 
(polyclonal; 1:750; Chemicon), Mac-3 (rat anti–mouse; 1:200; BD Bio-
sciences), and CNPase (monoclonal; 1:2,000; Sternberger Monoclonals). The 
infl ammatory index is defi ned by the average number of infl ammatory blood 
vessels per spinal cord cross section. 10–15 cross sections per animal were 
counted by two observers blinded to the genotypes of the mice. For the cere-
bellum, the number of cuff s was quantifi ed in two cerebellar sections per 
animal. To additionally analyze the CNS lesions, we counted Luxol Fast 
Blue/nuclear red–stained sections, and the relative proportions of demyelin-
ated areas (percentage with SEM) were determined using an ocular morpho-
metric grid as described previously (67). For human MS, paraffi  n-embedded 
material was obtained from the Archives of the Center for Brain Research, 
Medical University of Vienna. Double immunofl uorescence was performed 
with antibodies against CD68 and fi brin. Images were collected using an 
 Axioplan 2 Zeiss microscope with an Axiocam HRc camera or were processed 
for confocal microscopy using Olympus and Zeiss confocal microscopes.
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Rotarod behavior test. The rotarod assay was performed on a TSE Rota-
Rod apparatus (TSE Technical and Scientifi c Equipment GmbH) as de-
scribed previously (68). Rotarod assays were conducted with a 350-s 
maximum time limit, and means were collected for at least three trials. 
Statistical calculations were made by using Student’s t test.
Culture of primary microglia cells. Microglia were isolated from cul-
tures of mixed cortical cells as described previously (69). In brief, cortices 
from P1 mice were isolated and digested with trypsin (0.4%) for 20 min at 
37°C. Cells from four pups were plated onto poly-D-lysine–coated 75 cm2 
tissue culture fl asks. The culture medium (DMEM, 10% heat-inactivated 
FBS, and 1% Pen/Strep) was changed on day 2. After 2–3 wk in culture, the 
microglia were removed by the addition of 12 mM lidocaine (Sigma- Aldrich) 
and orbital shaking (180 rpm) for 20 min at 37°C. The cells were centrifuged 
(350 g), and the pellet was resuspended in complete medium and plated onto 
poly-D-lysine–coated tissue culture dishes. Microglia cell cultures were 
>95% pure as determined with three diff erent markers, IsoB4, IBA-1, and 
CD11b. To immobilize fi brinogen, tissue culture dishes were incubated 
overnight with 50 μg/ml fi brinogen (Calbiochem) in 20 mM Tris, pH 7.5, 
and 0.1 M NaCl at 37°C for all fi brinogen treatments. To serve as positive 
controls, LPS (Sigma-Aldrich) was added to the media at 1 μg/ml.
Phagocytosis assay. Phagocytosis assays were performed on both primary 
murine microglia and a murine microglia cell line (BV2). BV2 cells are an 
established cell line used to study microglia responses (47). BV2 cells were 
routinely passaged in DMEM, 20% heat-inactivated FBS, and 1% Pen/Strep. 
Microglia phagocytosis was assessed using the Vybrant phagocytosis assay kit 
(Invitrogen) according to the manufacturer’s recommendations. Microglia 
were cultured in 96-well plates at 5,000 cells/well for 36 h at 37°C. Blocking 
experiments included the addition of 1 μM LY294002 (Cell Signaling), 
10 μg/ml rat anti-CD11b (eBioscience), 10 μg/ml rat anti-TLR4 (eBio-
science), or 10 μg/ml rat IgG (Jackson ImmunoResearch Laboratories) to 
the media. Results were obtained from four separate experiments performed 
in triplicates. Statistical calculations were made by using Student’s t test.
Morphometry. Primary microglia were used for all morphologic analysis. 
Cells were plated on coated fi brinogen or in the presence of LPS for 72 h. Mi-
croglia were fi xed with methanol and immunostained with Isolectin B4 (1:300; 
Sigma-Aldrich). Blocking experiments involved the daily administration of 
10 μg/ml rat anti-CD11b (eBioscience), 10 μg/ml rat IgG (Jackson Immuno-
Research Laboratories), 200 μM γ377-395 peptide, or 200 μM of scramble 
peptide. Results were obtained from six separate experiments performed 
in duplicates. 250 cells per condition were counted for each individual 
 experiment. Activated microglia were quantitated as those cells >2,000 μm2. 
Images were collected using an Axioplan 2 Zeiss microscope with an Axiocam 
HRc camera and analyzed using the Axiovision 4.5 program (Carl Zeiss). 
Quantitation of cell area was performed using the Interactive Measurement 
feature of the Axiovision 4.5 program (Carl Zeiss MicroImaging, Inc.). Statis-
tical calculations were made by using Student’s t test.
Endotoxin detection assay. Fibrinogen samples were tested for contami-
nating endotoxins by a Limulus Amebocyte Lysate assay (E-TOXATE kit; 
Sigma-Aldrich). Fibrinogen-treated samples had undetectable endotoxin 
levels (<0.5 endotoxin units).
Immunoblots. Western blots were performed using standard protocols 
(65). Microglia were serum-starved overnight and plated on fi brinogen or 
with LPS for 6 h. Lysates were electrophoresed on 4–12% gradient SDS-
PAGE gels and probed with phospho and total Akt antibodies (1:1,000; Cell 
Signaling). RhoA activation was performed as described previously (70). In 
brief, 2 × 107 microglia were plated on fi brinogen for 6 h or with LPS for 
10 min. Cell lysates were incubated with GST-Rhotekin agarose beads (pro-
vided by J. Heller Brown, University of California, San Diego, San Diego, 
CA) for 45 min at 4°C. The beads were washed, resuspended in Laemmli 
sample buff er, and electophoresed on a 15% SDS-PAGE gel. Activated and 
total Rho were detected with mouse anti-RhoA (1:500; Santa Cruz Bio-
technology, Santa Cruz Biotechnology, Inc.). Densitometry was performed 
using the National Institutes of Health (NIH) Scion Image software using 
three blots from three separate experiments.
Deconvolution microscopy. Fluorescent images were obtained as de-
scribed previously (70). Primary microglia were stimulated with fi brinogen 
as described above. Cells were immunostained with antibodies to total actin 
(1:100; Sigma-Aldrich) or β-tubulin (1:100; Sigma-Aldrich).
Isolation of mouse splenocytes and T cell proliferation assay. Spleens 
were removed from control and fi brin-depleted mice after the induction of 
PLP139-151 EAE and washed in PBS. Spleens were mechanically dissociated 
with sterile blades and fi ltered through 70-μm nylon screens. Splenocytes 
were pelleted and washed with an erythrocyte lysing solution (Biolegend). 
Cells were washed twice with PBS, counted, and seeded at a density of 0.5 × 
106 cells/96 wells. Cells from both control and fi brin-depleted mice were 
either untreated or stimulated with 20 μg/ml PLP139-151, and proliferation 
was assayed by BrdU incorporation (Roche Applied Sciences) according to 
the manufacturer’s instructions.
FACS analysis. Primary mouse splenocytes were isolated from control 
and γ377-395 peptide–treated mice immunized with PLP139-151 on day 29 after 
 immunization. Cells were immunostained with antibodies to CD4, CD8, 
CD11b, CD11c, CD19, and B220 (1:100; Biolegend) and analyzed on a 
Becton Dickinson FACSCalibur fl ow cytometer.
Hematological analyses. Citrated plasma was prepared from mice admin-
istered intranasally 30 μg or 90 μg γ377-395 peptide or saline control daily for 
7 d. Plasma clotting times were measured by combining 10 μl of citrated 
plasma with 10 μl of 2U/ml bovine thrombin (Enzyme Research Laborato-
ries) and 40 mM CaCl2 in a weigh boat fl oating in a 37°C water bath. Time 
to clot was determined by mixing with a toothpick. Plasma thrombin times 
were established as described previously (15). Fibrin polymerization was 
evaluated by standard turbidity assays using plasma. In brief, citrate plasma 
(diluted tenfold in 20 mM Hepes, pH 7.4, containing 0.15 M NaCl and 
5 mM ε-amino caproic acid) was combined with bovine thrombin (fi nal 
concentration, 0.2 U/ml; Enzyme Research Laboratories) and Ca2+ (10 mM), 
and OD350 measurements were taken every 30 s.
Online supplemental material. Fig. S1 shows low power images of 
CD11b and fi brinogen double immunofl uorescence that demonstrates that 
fi brin depletion using ancrod decreases microglia activation in EAE. Fig. S2 
shows Luxol Fast Blue staining that reveals that fi brin depletion using ancrod 
reduces demyelinating lesions in EAE. Fig. S3 shows that there is no diff er-
ence in proliferation under untreated or PLP139-151–stimulated conditions 
between control and ancrod-treated mice subjected to PLP139-151 EAE. Fig. 
S4 shows FACS analysis of splenocytes using the markers CD4, CD8, 
CD11b, CD11c, CD19, and B220 that reveals that the γ377-395 peptide has 
no signifi cant eff ect on peripheral immune cells compared with control. Fig. 
S5 shows that a scramble γ377-395 peptide has no eff ect on progression of 
EAE. Fig. S6 shows high power images of Mac3 immunostaining in the spi-
nal cord of untreated and γ377-395 peptide–treated mice after the induction of 
EAE. The online supplemental material is available at http://www.jem.org/
cgi/content/full/jem.20061931/DC1.
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